Mensinger lists Common Stock sales (BBNX) including 7,200-share tranche on 01/02/2026

Rhea-AI Filing Summary

Michael Mensinger reported proposed sales of Common Stock on Form 144 relating to equity received for services to the issuer. The filing lists securities vested as Restricted Stock Units on 03/01/2026 and shows multiple sales in the past three months.

The filing records sales of 1,063 shares on 12/02/2025, 7,200 shares on 01/02/2026, 600 shares on 01/02/2026, and 2,200 shares on 01/06/2026, with amounts shown alongside each entry.

Insights

Corporate Governance Specialist

Routine affiliate resale notice with recent small-block sales reported.

The filing lists Restricted Stock Units vesting under a registered plan on 03/01/2026 and includes multiple sales by Michael Mensinger over the prior three months. Reported sale dates include 12/02/2025, 01/02/2026, and 01/06/2026, with share counts shown.

These entries are typical Section 144 notices that document intended or completed resale activity; cash‑flow treatment and any issuer proceeds are not specified in the provided excerpt. Subsequent filings would state settlement or additional sales if they occur.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza New York NY 10004	1064	13321.28	44382146	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2026	Restricted Stock Units vesting under registered plan	Issuer			1064	03/01/2026	Compensation for services rendered to Issuer

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Michael Mensinger c/o Beta Bionics, Inc. 11 Hughes Irvine CA 92618	Common Stock	12/02/2025	1063	31184.06
Michael Mensinger c/o Beta Bionics, Inc. 11 Hughes Irvine CA 92618	Common Stock	01/02/2026	7200	212832
Michael Mensinger c/o Beta Bionics, Inc. 11 Hughes Irvine CA 92618	Common Stock	01/02/2026	600	18118.14
Michael Mensinger c/o Beta Bionics, Inc. 11 Hughes Irvine CA 92618	Common Stock	01/06/2026	2200	66221.10

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Michael Mensinger's Form 144 for BBNX report?

The filing reports proposed sales of Common Stock by Michael Mensinger. It lists Restricted Stock Units vesting on 03/01/2026 and multiple past sales with dates and share counts shown.

How many shares did Mensinger sell in the past three months?

The filing lists four sales totaling specific share counts by date. Entries show 1,063, 7,200, 600, and 2,200 shares on the dates provided in the excerpt.

Are the dollar amounts of the sales disclosed in the Form 144 excerpt?

The excerpt shows numeric amounts adjacent to each sale entry but does not label them explicitly in the provided text. The lines include figures shown alongside each share count.

Did the Form 144 indicate the reason for the securities sold?

Yes. The filing links the securities to Restricted Stock Units vesting under a registered plan and identifies the disposition as compensation for services rendered to the issuer.

Does this Form 144 indicate whether proceeds go to the issuer?

The provided excerpt does not state who receives proceeds. The filing lists sales by the reporting person; cash‑flow treatment is not specified in the excerpt.